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http://dx.doi.org/10.1016/j.jmii.2012Cystic fibrosis (CF) is one of the most common autosomal recessive inherited disorders among
Caucasians. Comparatively, it is considered to be a rare disease among Asians. To date, only
a few cases of Taiwanese CF have been published. We report four CF cases from three families.
Case 1 was the first report of CF associated with a homozygosity for the CF transmembrane
conductance regulator gene (CFTR gene) mutation 3849þ10kb C->T in a Taiwanese patient.
Cases 2 and 3 had heterozygous c. 1898þ5 G->T and heterozygous p. I1023R (novel mutation)
for the CFTR gene mutation. Case 4 was homozygous for the CFTR gene mutation R553X being
reported in 2005 and complicated with cor pulmonale. These four patients had received
300 mg bid aerosolized tobramycin treatment every other month.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Cystic fibrosis (CF), an epithelial cell transport disorder
caused by mutations of the CF transmembrane conductance
regulator (CFTR) gene, is an autosomal recessive inherited
disorder of exocrine gland function, involving multiple
organ systems. CF is uncommon in Africa and Asia, with
a reported frequency of 1 in 350,000 in Japan.1 Previousnt of Pediatrics, Mackay
on 2 Chungshan North Road,
l.com (S.-D. Shyur).
an Society of Microbiology. Publ
.06.005studies reported that CF is quite rare among Taiwanese,
and until now, only 10 Taiwanese patients with CF (from
eight different families) have been reported.2,3 However,
we believe that the rate of CF is underestimated in Taiwan,
and that this may be due to our clinicians seldom believing
it to be one of the differential diagnoses.Case reports
Case 1
The patient was a 20-year-old female who had frequent
diarrhea and sinusitis with purulent nasal discharge andished by Elsevier Taiwan LLC. All rights reserved.
Cystic fibrosis 359nasal polyps before she was 13 years of age. Repeated
hospitalizations because of pneumonia with Pseudomonas
aeruginosa (P. aeruginosa) infection and bronchiectasis
with acute exacerbation were noted. In addition,
secondary amenorrhea 4 years ago and acute pancreatitis 2
years before were also noted.
Tracing back her family history, the patient had one
healthy younger brother, but her older sister had died at 4
months old with pneumonia, and her younger sister, who
had panbronchiolitis and bronchiectasis with recurrent P.
aeruginosa pneumonia, also expired at 16 years old due to
bronchiectasis and pneumothorax.
Her chest roentgenogram demonstrated hyperinflation,
interstitial pneumonitis with emphysema and tramline
appearance. High-resolution computed tomography showed
peribronchial thickening and bronchiectasis throughout
both lungs.
According to her clinical features, laboratory findings
and family history, CF was highly suspected. DNA analysis
was performed by direct sequencing of genomic DNA to
screen the entire CFTR gene and homozygosity for the CFTR
gene mutation 3849þ10kb C->T was identified.
The patient’s mother and younger brother were
heterozygous for the CFTR gene mutation 3849þ10kb C->T
(Fig. 1) and there were no clinical manifestations. Their
father did not receive DNA analysis. Nevertheless, because
the patient was homozygous for the CFTR gene mutation
3849þ10kb C->T, we consider that her father must be the
carrier of the heterozygous 3849þ10kb C->T gene mutation
too. Furthermore, although her younger sister had a nega-
tive sweat chloride test, we still highly suspect that she had
CF and was homozygous for the CFTR gene mutation
3849þ10kb C->T, because the gene mutation of 3849þ10kb
C>T is found in patients with a normal sweat chloride test.
Case 2
The patient, a 17-year-old boy with clubbing fingers, was
the first child of unrelated, healthy, native Taiwanese
parents. He had nasal obstruction and recurrent sinusitis
since early childhood and had received functional endo-
scopic sinus surgery (FESS) at 14 years of age. A persistent
night cough was noted since he was 2 months old, which
became productive and progressively worse since he was 8
years old. He was repeatedly hospitalized due to frequent
bronchiolitis and pneumonia since early childhood. P. aer-
uginosa pneumonia and methicillin resistant Staphylo-
coccus aureus (MRSA) pneumonia were proven by sputumFigure 1. The pedigree of patient 1.cultures numerous times. There were six pneumothorax
attacks since the age of 12 and pleurodesis at 15 years of
age. His chest roentgenogram showed diffused bronchiec-
tasis. Pulmonary function tests revealed: FEV1 Z 1.12 L
(37%), FVC Z 2.05 L (56%), FEV1/FVC Z 54%, FEF
25e75%Z 10% and TLCZ 3.3 L (73%). The flow-volume curve
scooped out with a reduced flow-volume slope and low
flows.
CF was suspected due to recurrent P. aeruginosa pneu-
monia and pneumothorax and was confirmed by gene
analysis with heterozygous c. 1898þ5 G->T and heterozy-
gous p. I1023R mutation (novel mutation) at the age of 16
years. His mother had a heterozygous mutation in p. I1023R
and his father had a heterozygous mutation in c. 1898þ5 G-
>T (Fig. 2). The patient became bed-ridden and oxygen
dependent at 16 years of age. After receiving tobramycin
300 mg bid every other month, he could walk by himself and
oxygen was needed occasionally when sleeping at night.
Case 3
The patient, a 16-year-old boy, was the younger brother of
Case 2. He also had recurrent sinusitis and nasal obstruction
with progressing severity since 5 years of age and had
received FESS at the age of 14. A dry cough had been noted
since he was 12 years old, which became productive and
progressively worse at 13 years of age. Recurrent P. aeru-
ginosa pneumonia was also noted. His chest roentgenogram
demonstrated diffused bronchiectasis. Pulmonary function
tests revealed FEV1 Z 2.35 L (61%), FVC Z 2.87 L (64%),
FEV1/FVCZ 82%, FEF 25e75%Z 55% and TLCZ 4.12 L (80%).
The slope of flow-volume curve was increased.
CF was suspected and also confirmed by DNA analysis,
with heterozygous c. 1898þ5 G->T and heterozygous p.
I1023R mutations (Fig. 2). In addition, due to intermittent
abdominal pain and heartburn sensation, a further survey
of the abdomen revealed gastroesophageal reflux,
a duodenal polyp and a hepatic hyperechoic lesion
(16.7  7.0  7.4 mm).
Case 4
An 8-year-old boy had chronic diarrhea and a failure to
thrive from the age of 2 months. He was also repeatedly
hospitalized because of pneumonia with P. aeruginosa andFigure 2. The pedigree of patients 2 & 3.
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childhood and had diffuse progressing bronchiectasis. In
addition, he had pancreatic insufficiency with fat malab-
sorption. His weight and height were both below the third
percentile. His chest roentgenogram demonstrated diffuse
bronchiectasis. High-resolution computed tomography
demonstrated peribronchial thickening, multiple areas of
bronchiectasis, and sputum plugs in both lung cavities.
CF was suspected and confirmed by DNA analysis with
homozygosity for the CFTR gene mutation R553X. Both of
his parents were heterozygous for the CFTR gene mutation
R553X (Fig. 3). His cardiac sonography showed severely
dilated right atrium (RA), right ventricle (RV), severe
tricuspid regurgitation (TR), pulmonary hypertension
(pressure gradient (PG) Z 63.8 mmHg) and minimal peri-
cardia effusion. The final diagnosis was CF with diffuse
bronchiectasis complicated with cor pulmonale.
Discussion
CF involves multiple organ systems, including the respira-
tory tract, the gastrointestinal tract, the genitourinary
tract and the sweat glands. It is the major cause of severe
chronic lung disease in Caucasians. In Asian populations,
the disease is rarely diagnosed definitively.
The CFTR gene is expressed in epithelial cells of the
respiratory tract, the gastrointestinal tract, the genitouri-
nary tract and the sweat glands. Defects in the 7q CFTR
gene, which encodes for a protein of regulatory function of
the chloride channel, produced a decrease in the secretion
of chloride and an increase in the reabsorption of sodium
and H2Oacross epithelial cells. A deficiency of water in the
mucous leads to a failure to clear mucous secretions.4
These secretions are retained in the airways, the pancre-
atic ducts, the biliary ducts and the vas deferens which
obstruct the canals, leading to dysfunction and increased
salt content in sweat and other serous secretions.
More than 1500 CFTR polymorphisms of five different
classes have been described. The gene mutation in Case 1
was 3849þ10kb C/T, which has an incidence of about 0.7%
worldwide.5 Cases 2 and 3 had heterozygous c. 1898þ5 G-
>T and heterozygous p. I1023R mutations. A point mutation
(1898 þ 5G–>T), located five base pairs downstream from
the donor splice site in intron 12 of the CFTR gene, has been
identified in CF patients of East Asian lineage, especially
those of Chinese origin.Figure 3. The pedigree of patient 4.In addition to Cases 2 and 3 in this report, the nucleotide
mutation of c. 1898þ5 G->Twas reported previously in four
Taiwanese patients.2 The homozygous R553X mutation in
Case 4 had defective regulation and the CFTR was not
activated by ATP or cyclic AMP; this is accounted for in 0.9%
of CF patients. Most of the R553X mutations are heterozy-
gous and only two cases of homozygosity for R553X have
been reported to date.2,5
The clinical manifestations of CF vary. Chronic cough
with purulent expectorated sputum and frequent pneu-
monia and bronchiolitis are the most common symptoms,
accompanied by a high prevalence of airways colonization
with S. aureus and P. aeruginosa (rare in other individuals).
All of our patients had recurrent pulmonary infections.
Pneumothorax occurs more frequently in older patients,
about 5e8% of CF patients, as compared to children and
teenagers. Pancreatic insufficiency induced by maldiges-
tion and malabsorption of fats and proteins (a hallmark of
the disease, 90% of patients by 1 year of age) is primarily
responsible for the failure to thrive. Gastroesophageal
reflux is more common in patients with CF than in normal
control patients. Case 3 also had this problem. Biliary
cirrhosis becomes symptomatic in only 2e3% of patients.
Puberty is usually delayed due to nutritional factors.
Adolescent females may experience secondary amenor-
rhea, especially with exacerbations of pulmonary disease,
such as in Case 1. Sweat is abnormally high in sodium and
chloride, both at rest and during exercise. Some CFTR
mutations, such as 3849þ10kb C/T and Arg117Hise7T
mutations have preserved sweat duct function.5 Case 1 had
a homozygous 3849þ10kb C->T gene mutation and normal
sweat chloride concentrations. CF complicated with cor
pulmonale was first reported at 1951. Autopsies have shown
cardiac involvement in 70% of children dying from CF; only
15% of these patients showed clinical right heart failure. In
CF, bronchial wall and parenchymal damage reduce intra-
pulmonary gas exchange. Alveolar hypoxia, chronic
inflammatory process and hypercapnia lead to pulmonary
vasoconstriction, pulmonary hypertension and alteration of
right ventricular structure or function. Right ventricular
failure occurs in 46% of CF patients at least 2 weeks before
death.6
A diagnosis of CF is based on laboratory evidence for
CFTR dysfunction, including two elevated sweat chloride
concentrations obtained on separate days (Cl > 60 mEq/L)
or the identification of two CF mutations or an abnormal
nasal potential difference measurement, in conjunction
with one or more of the following: presence of typical
clinical features (respiratory, gastrointestinal, or genito-
urinary), a history of CF in a sibling, or a positive newborn
screening test.7
Current CF treatments, which target respiratory infec-
tions, inflammation, mucociliary clearance, and nutritional
status, are associated with improved pulmonary function
and reduced exacerbations. The goal of therapy is to
maintain patients in a stable condition for prolonged
periods.
Aerosolized antibiotics, such as inhaled tobramycin, can
suppress chronic P. aeruginosa infections in patients with
moderate to severe disease, to improve lung function,
reduce exacerbations and decrease the risk of hospitaliza-
tion.8 Macrolide antibiotics are effective in the treatment
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controlled clinical trials have had proven clinical benefits in
CF.9 Bronchodilators, such as b-adrenergic agonists, can
relax smooth muscles, dilate bronchial passages, provide
symptomatic relief and facilitate clearance of the airway.
Two major goals of treatment of CF with cor pulmonale
are correction of hypoxemia and a decrease of RV after
load. Bronchodilators, cardiac glycosides (digoxin),
diuretics and vasodilators are effective in treating systemic
venous congestion of cor pulmonale in CF. Patients with
hypoxemia and cor pulmonale may benefit from long-term
use of oxygen in terms of improved survival and intellectual
function.10
Diet adjustments with regards to low fat, high protein,
high calorie diet and pancreatic enzyme replacement and
supplementary vitamins, are required to manage poor
exocrine pancreatic function.
CF is a life-limiting disorder, with a median cumulative
survival of 30 years. Lung disease accounts for nearly 85% of
cases of mortality. An irreversible loss of pulmonary func-
tion from low-grade infection can occur gradually and
without acute symptoms; early and aggressive treatment
can improve the outcome. Patients whose respiratory tract
cultures yield P. aeruginosa have a poorer outcome than
those without these organisms.
We believe CF in Taiwan has been underestimated due
to the lack of clinical suspicion. In patients with bronchi-
ectasis and recurrent pulmonary infection, especially those
with family history of early death, CF should be one of the
differential diagnoses; aggressive intervention is indicated
in such patients. In addition, regular evaluation and
adjustments are indicated for subsequent complications.
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